Elicio Therapeutics Inc

ELTXNASDAQ · USD
1.48USD0.00 (-1.34%)
152

Elicio Therapeutics Inc (ELTX) Historical Volatility

ELTX's 30 day historical volatility is 95.85%, in the 76th percentile of readings over the past year. This is a high percentile, meaning Elicio Therapeutics Inc shares have swung far more than usual. ELTX's 30 day implied volatility sits at 264.93%, with an IV Rank of 63.49%, leaving IV 169.08 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking ELTX historical volatility helps you see how much Elicio Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ELTX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ELTX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ELTX's 30 day historical volatility, or ELTX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ELTX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.

Historical Volatility

HV Percentile
76thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)95.85%

HV Percentile76th

Implied Volatility (30d)264.93%

IV Rank63.49%

IV Minus HV+169.08%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →